Beta Bionics, Inc. (BBNX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-01-14

Key Insights

The Form 4 filing indicates that Gerard J. Michel, a director of Beta Bionics, Inc., has acquired 3,997 shares of the company's common stock through a restricted stock unit award.
The transaction suggests that the director has increased his direct ownership in the company, potentially signaling his confidence in the company's future prospects.
Investors should monitor insider trading activities, as they can provide insights into management's views on the company's valuation and growth potential.

Want the newest filings?

This analysis covers the filing from 2026-01-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-14

Danny L. Dearen, a director of Beta Bionics, Inc., acquired 3,997 shares of the company's common stock through a restricted stock unit award under the 2025 Equity Incentive Plan.
This insider transaction suggests Dearen's confidence in the company's future and aligns his interests with those of other shareholders.
The acquisition of these shares increases Dearen's direct beneficial ownership in Beta Bionics to 15,244 shares.

Filed: 2026-01-14

Adam Lezack, a director of Beta Bionics, Inc., has acquired 3,997 shares of the company's common stock. This insider buying activity may signal the director's confidence in the company's prospects.
The transaction was an acquisition of restricted stock units, which suggests the director is being compensated and incentivized to align his interests with those of the company and its shareholders.
The number of shares acquired represents a relatively small portion of the director's total beneficial ownership, which stands at 12,432 shares following the reported transaction.

Filed: 2026-01-14

Christy Jones, a director of Beta Bionics, Inc., acquired 3,997 shares of common stock through a restricted stock unit award, increasing her direct beneficial ownership to 15,244 shares.
The acquisition of shares by a director suggests their confidence in the company's future performance and aligns their interests with those of other shareholders.
Investors should monitor insider trading activity, as it can provide insights into management's perspectives on the company's prospects.

Filed: 2026-01-14

Insider Maria Palasis acquired 3,997 shares of Beta Bionics, Inc. (BBNX), increasing her direct ownership to 12,432 shares.
The transaction was through a restricted stock unit award granted under the company's 2025 Equity Incentive Plan, suggesting the company is incentivizing and retaining key leadership.
Insider buying can signal management's confidence in the company's prospects, which may be positive for investors.

Filed: 2026-01-14

Sean Carney, a director of Beta Bionics, Inc., has acquired 3,997 shares of the company's common stock, increasing his direct ownership to 15,244 shares.
The acquisition appears to be a restricted stock unit award granted under the company's 2025 Equity Incentive Plan, suggesting an alignment of Carney's interests with those of the company and its shareholders.
Insider transactions, such as this acquisition, can provide insight into management's confidence in the company's prospects and their commitment to creating shareholder value.

Filed: 2026-01-07

Mike Mensinger, the Chief Product Officer of Beta Bionics, Inc., has sold 2,200 shares of the company's common stock pursuant to a pre-planned 10b5-1 trading plan.
The shares were sold at a weighted average price of $30.1005 per share, and Mensinger still holds 80,752 shares directly after the transaction.
This insider sale, while routine, could indicate Mensinger's confidence in the current stock price or a need for personal liquidity, and should be monitored by investors for any larger or more frequent selling patterns.

Other reports for Beta Bionics, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.